Stockreport

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics, Inc.  (KLRS) 
PDF Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027 I [Read more]